Business Wire

Airway Therapeutics Wins 2024 ATS Whitsett Award for Abstract of Positive Phase 1b Results of Zelpultide Alfa in Preterm Neonates at Risk of Bronchopulmonary Dysplasia

Share

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced today it received the Whitsett Award for highest scoring abstracts from the Neonatal and Developing Lung Executive Committee at the American Thoracic Society (ATS) 2024 International Conference.

The abstract is titled “Randomized Blinded Phase 1b Study Demonstrates Safety and Tolerability of Zelpultide Alfa (rhSP-D) in Preterm Neonates at High Risk for the Development of Bronchopulmonary Dysplasia (BPD).” Thirty-seven infants, born at 23 weeks to 28 weeks and 6 days, were enrolled in the study in the US and Europe. No dose limiting toxicities were found while indications of efficacy were observed.

As many as 2.5 million very preterm infants globally are at risk of developing BPD from lung damage caused by mechanical ventilation and oxygen support. Babies who develop BPD can suffer lifelong complications such as asthma and pneumonia as well as growth and developmental problems.

The Whitsett Award is named for Jeffrey A. Whitsett, M.D., Director of the Section of Neonatology, Perinatal and Pulmonary Biology at Cincinnati Children's Hospital Medical Center. Raquel Arroyo, Ph.D., PharmD, Airway’s Director of Clinical Sciences, accepted the award as lead author of the abstract.

“We are grateful to the parents of these fragile patients participating in the first clinical study with zelpultide alfa in very preterm neonates, and also thank the investigators and their study teams for their participation,” said Airway CEO and Chief Medical Officer Marc Salzberg, M.D. “Dr. Arroyo proudly received the Whitsett award on behalf of the investigators and in recognition of her invaluable contribution to the development of zelpultide alfa. Based on the successful completion of the Phase 1b study we plan to launch a pivotal multinational trial in Q4/2024 enrolling more than 300 neonates born at 23 weeks to 27 weeks and 6 days.”

The pivotal trial, which will begin in Spain and Italy, will be a randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy of zelpultide alfa (administered intratracheally) in preventing BPD compared to standard of care plus air-sham (intratracheal administration of room air).

Zelpultide alfa is a recombinant version of the endogenous human SP-D, a protein essential to the lung’s immune defense in reducing inflammation and infection while modulating immune responses. The biologic is administered intratracheally during mechanical ventilation. The FDA and European Medicines Agency have granted orphan drug status to zelpultide alfa.

About Airway Therapeutics

Airway Therapeutics is a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, beginning with the most vulnerable populations. The company is advancing zelpultide alfa, a novel recombinant human protein hSP-D that reduces inflammation and infection in the body while modulating the immune response. Zelpultide alfa is Airway’s first candidate in development for prevention of BPD in very preterm infants and for treatment of COVID/CAP in seriously ill mechanically ventilated patients.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240624070940/en/

Contacts

Media contact:
Meghan Riley
riley@airwaytherapeutics.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ravenna, City of Mosaics, UNESCO World Heritage Site, in Partnership with EnChroma and Fondazione Paolina Brugnatelli, Enables Color Blind Visitors to Rediscover the Colors of Mosaics15.7.2024 19:08:00 EEST | Press release

Opera di Religione della Diocesi di Ravenna, EnChroma, manufacturers of lenses for color blind users, Francesca Carlone, sustainable designer and founder of the project, Fondazione Paolina Brugnatelli and ITRIA announce today an initiative to enhance the experience of color blind visitors. Starting July 19, 2024, visitors with this vision condition will be able to borrow special glasses during their visit to live for the first time the experience of seeing light and bright color mosaics. The project, called ColoRaMi - color mosaics, will be introduced on July 19 at Basilica di Sant’Apollinare Nuovo as part of the Ravenna Mosaici FOR ALL program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240714597763/en/ Basilica di San Vitale: Agnus Dei. Normal colour vision and colour blind view (Graphic: Business Wire) In Italy, approximately 2.5 million people are color blind, a vision condition affecting a higher number of men (8%)

Patient Safety Movement Foundation Presents 11 th Annual World Patient Safety, Science & Technology Summit on September 6-7, 202415.7.2024 18:30:00 EEST | Press release

The Patient Safety Movement Foundation (PSMF) is bringing together some of the world’s foremost experts and advocates on patient safety at their 11th annual World Patient Safety, Science & Technology Summit on September 6-7, 2024. Hosted on the campus of the University of California, Irvine, a hub for innovative research, the two-day conference will address some of the most critical issues and pioneering solutions around protecting patients from preventable harm in healthcare settings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240715610848/en/ Patient Safety Movement Foundation's 11th Annual World Patient Safety, Science & Technology Summit, September 6-7, at the University of California, Irvine (Photo: Business Wire) Distinguished speakers from around the world will discuss and present on groundbreaking solutions in patient safety, including leveraging real-time data from electronic medical records, the transformative

Zayed Sustainability Prize Demonstrates Global Reach and Impact with over 5,900 Submissions15.7.2024 17:54:00 EEST | Press release

The Zayed Sustainability Prize, the UAE's pioneering global award for sustainability and humanitarianism, has officially closed entries for its 2025 awards cycle. A total of 5,980 applications were received across the six Prize categories of Health, Food, Energy, Water, Climate Action and Global High Schools, from 156 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240715270226/en/ Zayed Sustainability Prize Demonstrates Global Reach and Impact with over 5,900 Submissions (Graphic: AETOSWire) The Zayed Sustainability Prize winners will be announced at the Awards Ceremony, which will be held on 14 January 2025 as part of Abu Dhabi Sustainability Week. This year’s Prize has seen a notable 15% increase in submissions over the previous year from small and medium enterprises (SMEs), nonprofit organisations, and high schools. Close analysis of the submissions reveals a prevailing trend across all categories: a significan

Laserfiche Earns Top Overall Ranking in Nucleus Research Content Services and Collaboration Value Matrix 202415.7.2024 17:00:00 EEST | Press release

Laserfiche — the leading SaaS provider of intelligent content management and business process automation — is a Leader in the Nucleus Research Technology Value Matrix for Content Services and Collaboration for the ninth year in a row. Among the vendors evaluated, Laserfiche ranks highest overall in both functionality and usability. “Laserfiche is recognized as a leader for its strong intelligent document processing and automation capabilities with built-in analytics, security and AI-powered productivity tools,” said Evelyn McMullen, research manager at Nucleus Research and author of the report. “Laserfiche’s roadmap demonstrates a commitment to AI innovation that will enable users to glean additional insights from their content while making information management and process automation even easier.” With cloud, on-premises and hybrid deployment models, Laserfiche empowers customers with scalable and low-code/no-code solutions for business process automation, intelligent data capture, d

Westlake Implements Succession Plan15.7.2024 16:28:00 EEST | Press release

Westlake Corporation (NYSE: WLK) (the “Company” or “Westlake”) today announced that Jean-Marc Gilson, who most recently served as President and Chief Executive Officer of Mitsubishi Chemical Group Corporation, has been appointed by the Board of Directors to serve as President and Chief Executive Officer of Westlake. Jean-Marc Gilson succeeds Albert Chao, who will transition to become Executive Chairman of the Westlake Board of Directors. James Chao, the current Chairman of the Board, will become Senior Chairman of the Westlake Board of Directors. These appointments take effect today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240715044647/en/ Jean-Marc Gilson, new President and Chief Executive Officer of Westlake Corporation (Photo: Business Wire) “I am excited to welcome Jean-Marc as the newest addition to Westlake’s management team. Westlake is in a very strong position supported by a world-class team, and, having serv

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye